AREV Life Sciences Global Corp. (CSE:AREV) (OTC:AREVF) (CNSX:AREV.CN) (“AREV” or the “Company”) is pleased to announce the Company has closed on the purchase of Wright and Well Essentials Inc. (“Wright & Well”) in an all cash deal.

AREV Life Sciences Global Corp. has  purchased Wright & Well, a company with an extensive Hemp and Cannabis line of branded products currently being sold in 10 dispensaries in Oregon.

The acquisition of Wright & Well for an all cash deal of twenty thousand ($20,000) dollars includes but is not limited to:

• A line of full branded products, currently available on the Wright Well website www.wrightandwell.com 

• All finalized branding, packaging and website 

• Raw materials currently in inventory 

The raw materials, products and packaging valued at $175,000 as of the last audited financial statements.

This acquisition further expands the depth of the company’s core competencies. The products have been formulated using ingredients from Ayurvedic Medicine and Cannabinoids.  The company plans to apply its nano-particularization methods to the formulations which will increase the bio-availability and effectiveness of each product and provide a competitive advantage over other cannabinoid products in the market.  During the past serval months the company has also assembled a Scientific Advisory Board comprised of some of the worlds experts in hemp and cannabinoid sciences. The Arev team of scientific advisors contributing to the ongoing review, lab analysis and clinical trials are:

Dr. Robert Melamede has a Ph.D. in Molecular Biology and Biochemistry from the City University of New York. Dr. Melamede is recognized as a leading authority on the therapeutic uses of cannabis, and has authored or co-authored dozens of papers on a wide variety of scientific subjects. He is considered one of the world's leading experts on the human endocannabinoid system, the complex biological network of neurotransmitters and cell receptors that he calls "the great and powerful wizard behind the curtain.” Dr. Bob as he known, is also Program Director Phoenix Tears, (Denver CO).

Dr. Uma Dhanabalan reviews medical records, medications and blood work in family medicine and preventative wellness from her clinic in Massachusetts .  As an advocate of holistic treatments; Uplifting Health & Wellness Clinic provides Medicinal Marijuana Card examinations.  Dedicating 40-years experience as a Harvard graduate, Dr. Uma Dhanabalan understands the human healing process with Integrative Cannabinology, Functional Endocannabinology and Cannabinoid Medicine.

Dr Jay Noller Dr. Noller is a professor emeritus at Oregon State University (OSU) and is the founding director and lead researcher of OSU's Global Hemp Innovation Center (GHIC). He was the lead in writing the application which was recently awarded a $10 million grant from the U.S. Department of Agriculture to define economic opportunities for hemp in the western United States. GHIC is the world's most comprehensive research center devoted to the study of hemp, providing the most comprehensive knowledge of hemp innovation to be found anywhere. GHIC is advancing the research of hemp and its market potential across multiple diverse industries and research fields to serve the growing international demand for innovative approaches to food, health, and fiber. Dr. Noller has been Oregon's leader in hemp research and policy since 2014 and has developed research partnerships with over 40 institutions globally devoted to improving hemp genetics and modes of production and processing for fiber, grain essential oils and advances in new classes of hemp varieties. He has directed hemp research and related industrial projects across North America, China, and Europe. 

Dr. Richard van Breeman is at the Department of Pharmaceutical Sciences in the Oregon State University College of Pharmacy and in 2021 was named one of the world’s most influential analytical scientists by The Analytical Scientist

magazine for the second year in a row. He is an expert in biomedical mass spectrometry with a focus on natural products, researches the discovery of drugs from botanicals and investigates the safety and efficacy of botanical dietary supplements. This research integrates the analytical tool of mass spectrometry into all aspects of the drug discovery

and development from screening of botanical extracts for the identification of active natural products, to studies of drug metabolism and disposition, and to quantitative analyses of the bioavailability and pharmacokinetics of pharmacologically active compounds. These translational studies extend from basic science to clinical trials.

Dr. Harold Smith is the founder of Cannametrix, LLC., a testing lab with a strategic different approach for establishing new standards for quality control and efficacy of medicinal cannabis. Dr. Smith is a full professor at University of Rochester in the Department of Biochemistry and Biophysics and founder and CEO of OyaGen, Inc. he coordinated a group of Ph.D. scientist in drug discovery for viral diseases. Oyagen recently sold a drug to treat Covid 19.

Mike Withrow, Chief Executive Officer of Arev, commented: “This acquisition enables the company to accelerate its US and Canadian therapeutic wellness market. It leverages Arev's core competency of extraction and provides a turkey branded line”. Mr. Withrow continued: “We remain committed to Arev's development on the biomedicinalization of target compounds from botanicals, fungi and select sea animals such as sea cucumber. The results of this work can now be directly applied for the use in Wright & Well Branded products.”   Visit www.wrightandwell.com to see our new product line and to order products.

The company would also like to announce it has received the Dear Colleague Letter “DCL” titled “The Need to Revise and Amend Ready-To-Use-Therapeutic Food Regulations and Legislation” from its Strategic Advisory Firm in Washington DC. The letter has the support from the necessary House Members to be presented in the 118th CONGRESS 1st Session for the House of Representatives. The company will be providing an update in the coming weeks on the development and activity on the RUTF it continues to work on in collaboration with Voynich Biosciences as previously announced.

For further information, contact Mike Withrow, This email address is being protected from spambots. You need JavaScript enabled to view it. 778-929-6536. For more information visit www.arevlifesciences.com. 

On behalf of the Board,

Mike Withrow
CEO & Director

About AREV Life Sciences Global Corp.

AREV is an early-stage life science discovery enterprise dedicated to delivering solutions to public health through discovery, collaborations in the life science industry, and pathogen remediation. AREV is invested in commercial innovations in phytomedicinal discoveries of small molecule antivirals and for related neglected chronic co-morbidities and innovations human nutrition including the late-stage development of a Ready-to-Use Therapeutic Food (RUTF) for Severe Acute Malnutrition (SAM) and an Enteral Formula targeting the long-term effects of chronic infection. AREV is dedicated to designing and delivering innovation in rational drug design, driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. AREV is a member of both BIOTECanada and The Biotechnology Innovation Organization (BIO).

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required

under the applicable laws. This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements.  Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements

address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com.